EMEA-000876-PIP05-15-M04
Key facts
| Invented name |
Soliris
|
| Active substance |
Eculizumab
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0388/2020
|
| PIP number |
EMEA-000876-PIP05-15-M04
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of myasthenia gravis
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Alexion Europe SAS
E-mail: pip.enquiries.eu@alexion.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|